- Home
- SPPL vs NLSP Comparison
SPPL vs NLSP Comparison
Compare SPPL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- NLSP
- Stock Information
- Founded
- SPPL 2016
- NLSP 2015
- Country
- SPPL Singapore
- NLSP Switzerland
- Employees
- SPPL N/A
- NLSP N/A
- Industry
- SPPL
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- NLSP Health Care
- Exchange
- SPPL Nasdaq
- NLSP Nasdaq
- Market Cap
- SPPL 10.4M
- NLSP 12.4M
- IPO Year
- SPPL 2023
- NLSP 2021
- Fundamental
- Price
- SPPL $2.78
- NLSP $2.68
- Analyst Decision
- SPPL
- NLSP
- Analyst Count
- SPPL 0
- NLSP 0
- Target Price
- SPPL N/A
- NLSP N/A
- AVG Volume (30 Days)
- SPPL 9.1K
- NLSP 325.4K
- Earning Date
- SPPL 01-01-0001
- NLSP 07-07-2025
- Dividend Yield
- SPPL N/A
- NLSP N/A
- EPS Growth
- SPPL N/A
- NLSP N/A
- EPS
- SPPL N/A
- NLSP N/A
- Revenue
- SPPL $2,764,846.00
- NLSP N/A
- Revenue This Year
- SPPL N/A
- NLSP N/A
- Revenue Next Year
- SPPL N/A
- NLSP N/A
- P/E Ratio
- SPPL N/A
- NLSP N/A
- Revenue Growth
- SPPL N/A
- NLSP N/A
- 52 Week Low
- SPPL $2.02
- NLSP $1.30
- 52 Week High
- SPPL $16.80
- NLSP $16.00
- Technical
- Relative Strength Index (RSI)
- SPPL 45.02
- NLSP 62.59
- Support Level
- SPPL $2.57
- NLSP $2.19
- Resistance Level
- SPPL $2.86
- NLSP $2.54
- Average True Range (ATR)
- SPPL 0.19
- NLSP 0.19
- MACD
- SPPL 0.02
- NLSP -0.01
- Stochastic Oscillator
- SPPL 38.26
- NLSP 57.89
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.